We are expanding both commercial and clinical manufacturing capacity across our global network with more than €2 billion invested until 2035. This will help our customers accelerate development, scale production, and secure a reliable supply throughout the product lifecycle.
To support the growing demand for our products, we are substantially increasing our aseptic manufacturing and packaging capabilities in Europe. The expansion of our existing production sites and our new commercial manufacturing facility, which is currently under construction, will strengthen our global production network and provide additional capacity for large-scale supply.
Key investments include:
These investments enable greater manufacturing flexibility and provide customers with enhanced capacity for future commercial success.
Supporting emerging therapies requires reliable and scalable clinical manufacturing infrastructure. To meet increasing demand from biotech innovators, we continue to expand our clinical manufacturing capabilities.
Key investments include:
